Answers are grounded in this paper and cite their sources.
Examines how naringin improves antigen cross-presentation in immune cells, indicating a new cancer therapy approach.
Successful immune checkpoint inhibitor (ICI) treatment of cancer requires adequate infiltration of cytotoxic CD8+T lymphocytes (CTLs) in tumors. Previous studies have identified the compound naringin, which increases CTL infiltration and rescues ICI efficacy in CTL-lacking tumors, and cancer CTL priming has been shown to rely on antigen cross-presentation (XPT). Therefore, the present study aimed to examine the effect of naringin on XPT by various human and murine antigen-presenting cells (APCs). The results indicated that naringin increases XPT by XPT-competent APCs, including murine bone marrow (BM) dendritic cells, peritoneal macrophages (MΦs), and human monocyte-derived dendritic cells (HMDCs). However, XPT was not observed with BM- or human monocyte-derived MΦs with or without naringin. Naringin reduced the activity of lysosomes, suppressing the degradation of internalized antigens, thereby increasing antigen cytosolic escape and MHC class I molecule-presenting antigens. In addition, human lymph node (LN) sinus MΦs were transcriptomically more similar to XPT-competent HMDCs than other LN MΦ groups. Taken together, these data suggest that naringin promotes XPT by XPT-competent APCs, which may explain why naringin was found to promote cancer immunity in our previous studies. This finding highlights the potential for developing cancer immunotherapies that induce XPT, offering a promising strategy to enhance antitumor immune responses.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: